This national initiative, a collaborative partnership with Eli Lilly & Company, Dementias Platform UK, Oxford Health FT, Greater Manchester Mental Health FT, University Hospitals Sussex FT, and Sheffield Teaching Hospitals FT, aims to transform early diagnosis of Alzheimer’s disease by testing the scalability of biomarker diagnostics across diverse communities. The project is piloting a clinical pathway for the early and accurate diagnosis of AD, including biomarker assessment via cerebrospinal fluid (CSF) which hopefully can then be implemented across other NHS Trusts.
Earlier this year, the project was recognised by HSJ as the Best Pharmaceutical Partnership with the NHS, and we are proud to see its continued impact celebrated at the highest level. This achievement reflects the strength of our partnership and the value of collaborative working.
The HSJ Awards are among the most respected accolades in UK healthcare, celebrating excellence, innovation, and partnership across the sector.
Speaking after the award, Prof Vanessa Raymont, who is leading the study at DPUK said:
“This is a real tribute to the whole team. The achievement reflects the strength of our partnership and the value of collaborative working to achieve early Alzheimer’s disease diagnosis.”